Get the Stockscreener App
32.89
1.17%
0.38
After Hours:
32.89
Tarsus Pharmaceuticals Inc stock is traded at $32.89, with a volume of 300.10K.
It is up +1.17% in the last 24 hours and up +21.32% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
See More
Previous Close:
$32.51
Open:
$32.42
24h Volume:
300.10K
Relative Volume:
0.41
Market Cap:
$1.26B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-9.7308
EPS:
-3.38
Net Cash Flow:
$-123.00M
1W Performance:
-0.87%
1M Performance:
+21.32%
6M Performance:
-9.52%
1Y Performance:
+85.09%
1-Day Range:
$32.23
$33.66
1-Week Range:
$31.36
$33.95
52-Week Range:
$12.57
$42.50
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Tarsus Pharmaceuticals' SWOT analysis: stock surges on XDEMVY success By Investing.com - Investing.com Canada
Taking the lead: Tarsus Pharmaceuticals Inc (TARS) - SETE News
Tarsus Pharmaceuticals' SWOT analysis: stock surges on XDEMVY success - Investing.com India
Driehaus Capital Management LLC Purchases 203,300 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Frazier Life Sciences Management L.P. Reduces Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals Inc [TARS] Records 200-Day SMA of $29.59 - Knox Daily
How did Tarsus Pharmaceuticals Inc (TARS) fare last session? - US Post News
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024 - GlobeNewswire
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024 - StockTitan
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Holdings Decreased by Ensign Peak Advisors Inc - MarketBeat
Tarsus Pharma maintains stock target on ECP feedback - Investing.com
Federated Hermes Inc. Acquires 11,018 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Rhumbline Advisers Acquires 6,070 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care Innovations (NASDAQ:TARS) - Seeking Alpha
Midday Stock Roundup: Staar Surgical Up - Orange County Business Journal
Tarsus Pharmaceuticals Inc [TARS] Shares Jump Approximately 103.53% Over the Year - Knox Daily
Tarsus Pharmaceuticals Inc (TARS) expanding its growth trajectory ahead - SETE News
Trane Technologies (NYSE:TT) Sets New 52-Week High at $382.49 - MarketBeat
Taking a look at what insiders are doing to gauge the Trane Technologies plc (TT)’s direction - Knox Daily
Closing Figures Unveiled: Traws Pharma Inc. (TRAW) Drop -10.26, Closes at 0.31 - The Dwinnex
Traws Pharma Inc. (TRAW) Stock: A Comprehensive 52-Week Review - The InvestChronicle
2024Risk of supply problem | Theratechnologies issues warning, shares lose 15% - Actual News Magazine
Tarsus Pharmaceuticals (NASDAQ:TARS) Trading Up 3.6% - MarketBeat
Transense Technologies (LON:TRT) Sets New 1-Year High at $194.90 - Defense World
Financial Health Check: Examining Tarsus Pharmaceuticals Inc (TARS)’s Key Ratios - The Dwinnex
A stock that deserves closer examination: Tarsus Pharmaceuticals Inc (TARS) - US Post News
If You Invested $1000 in Trane Technologies a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Trane Technologies plc (NYSE:TT) Shares Sold by CCLA Investment Management - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Down 5% - MarketBeat
Traws Pharma Announces Stock Split, Share Adjustments, and Growth Strategy - TipRanks
Trane Technologies PLC stock rises Tuesday, outperforms market - MarketWatch
Traws Pharma, Inc. Announces Special Shareholders Meeting Results - GlobeNewswire
TT stock rated an Overweight by Morgan Stanley - Knox Daily
Penny stock under Rs 90 hit upper circuit as company receives new order worth Rs 139,48,00,000 from Maharashtra State Infrastructure Development Corporation - Dalal Street Investment Journal
Infra stocks hits 5% upper circuit after receiving order worth ₹ 139 Cr for highway work - Trade Brains
Tarsons Products: Industry indicators point to recovery - Moneycontrol
The Attractiveness of Investing In Tarsus Pharmaceuticals Inc (TARS) is Growing - Knox Daily
CORRECTING and REPLACING TARO Investors Have Opportunity to Lead Taro Pharmaceutical Industries Ltd. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Trane Technologies PLC stock rises Monday, outperforms market - MarketWatch
Cantor Fitzgerald Upgrades Teradyne, Inc. (TER) to an Overweight from a Neutral - Knox Daily
TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - PR Newswire
Bank of New York Mellon Corp Grows Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by Analysts - MarketBeat
TD Asset Management Inc Sells 13,200 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
TD Asset Management Inc Decreases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Recommendation of “Buy” from Analysts - Defense World
Trane Technologies PLC stock rises Friday, outperforms market - MarketWatch
Are Smart Investors Making the Right Decision? Trane Technologies plc (TT) - SETE News
Prepare Yourself for Liftoff: Tarsus Pharmaceuticals Inc (TARS) - SETE News
Insider Selling: LINK WILLIAM J PHD, Tarsus Pharmaceuticals Inc [TARS] Director divested 35,000 shares - Knox Daily
Questex’s Fierce Pharma Announces the 2024 Fierce Pharma Marketing Awards Winners - GlobeNewswire Inc.
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):